Sector News

Lilly appoints Philip Johnson to Senior Vice President and Treasurer

November 14, 2017
Life sciences

Eli Lilly and Company has announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018.

Johnson currently serves as vice president for Investor Relations at Lilly. He will report to Joshua Smiley, who will become senior vice president and chief financial officer effective January 1, 2018. Johnson will continue to lead Lilly’s investor relations efforts.

“Phil has been a trusted partner for our shareholders, effectively communicating the company’s results and expectations, while ensuring management’s actions are informed by shareholder input,” Smiley said. “With his external focus and experience in the capital markets, Phil is an ideal candidate to assume this important position and to help guide Lilly’s financial strategy.”

Johnson has been with Lilly 22 years, serving in a variety of financial roles in the U.S. and overseas. He has been in his current role since 2007 and before that was vice president, Finance, and chief financial officer for Global Manufacturing and Quality. Prior to joining Lilly, Johnson worked for six years in investment banking and management consulting in the U.S. and Europe.

Source: Eli Lilly and Company

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.